

VI. Literaturverzeichnis

1. **Tracy S., Chapman N.M., McManus B.M., Pallansch M.A., Beck M.A., Carstens J.:** A molecular and serologic evaluation of enteroviral involvement in human myocarditis. *J. Mol. Cell. Cardiol.* (1990), 22(4): 403-414.
2. **Mertens T., Kruppenbacher J.P.:** Virusmyokarditis und klassische Virologie, klinisch-virologische und experimentelle Daten. *Monatsschr. Kinderheilkd.* (1990), 138: 184-189.
3. **Schultheiss H.P.:** Virusmyokarditis – Neue Aspekte zum Pathomechanismus, zur Diagnose und zur Therapie. *Wien. Klein. Wochenschr.* (1988), 100(24): 779-786.
4. **Weiss L.M., Movahed L.A., Billingham M.E., Cleary M.L.:** Detection of Coxsackievirus B3 RNA in myocardial tissue by the polymerase chain reaction. *Am. J. Pathol.* (1991), 138(2): 497-503.
5. **Krause E.G., Bartel S., Beyerdorfer I., Wallukat G.:** Activation of cyclic AMP-dependent protein kinase in cardiomyocytes by anti-beta 1-adrenoceptor autoantibodies from patients with idiopathic dilated cardiomyopathy. *Blood Press Suppl.* (1996), 3: 37-40.
6. **Rose N.R., Hill S.L.:** Cellular and molecular mechanisms of murine autoimmune myocarditis. *APMIS* (1997), 105 (1): 1-13.
7. **Seko Y., Yamazaki T., Shinkai Y., Yagita H., Okumura K., Naito S., Imataka K., Fujii J., Yazaki Y.:** Cellular and molecular bases for the immunopathology of the myocardial cell damage involved in acute viral myocarditis with special reference to dilated cardiomyopathy. *Jpn. Circ. J.* (1992), 56: 1062-72.
8. **Moisier D.E., Gulizia R.J., Baird S.M., Wilson D.B.:** On the SCID's? *Nature* (1989), 338: 211.
9. **Herskovitz A., Ahmed-Ansari A., Neumann D.A., Beschorner W.E., Rose N.R., Soule L.M., Burek C.L., Sell K.W., Baughman K.L.:** Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. *J. Mol. Cell. Cardiol.* (1990), 15(3): 624-632.

10. **Bojum A.:** Isolation of lymphocytes, granulocytes and macrophages. *Scand. J. Immunol. (1976), 5 Suppl. 5: 9-15.*
11. **Zimin Y.I., Sumarokov A.V., Tereshchenko S.E.:** Immune cytotoxic mechanism of myocardial lesion in non-specific Myocarditis and idiopathic dilated cardiomyopathy. *Cor. Vasa. (1988), 30(2): 127-134.*
12. **Maisch B., Schwab D., Sandhage K., Schmaltz A.A., Wimmer M.:** Sekundäre Immunpathogenese bei Myokarditis, Herzmuskelerkrankungen und infarktassozierten Rhythmusstörungen im Kindes- und Erwachsenenalter. *Wien. Klin. Wochenschr. (1989), 101(1): 31-39.*
13. **Maisch B., Outzen H., Roth D., Hiby A., Herzum M., Henstenberg C., Hufnagel G., Schönian U., Hochsiek K.:** Prognostic determinants in conventionally treated myocarditis and perimyocarditis – focus on antimyolemnal antibodies. *Eur. Heart J. (1991), 12 Suppl. D: 81-87.*
14. **De Schreer I.K., De Buyzere M., Delanghe J., Maas A., Clement D.L., Wieme R.:** Humoral immune response against contractile proteins (actin and myosin) during cardiovascular disease. *Eur. Heart J. (1991), 12 Suppl. D: 88-94.*
15. **Maisch B., Weyerer O., Hufnagl G., Hengstenberg C., Schönian U., Haverich A., Kochsiek.:** The vascular endothelium as target of humoral auto-reactivity in myocarditis and rejection. *Z. Kardiol. (1989), 78 Suppl. 6: 95-99.*
16. **Wolf P.G., Kühl U., Schultheiß H.P.:** Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. *Am. Heart J. (1989), 177(6): 1303-1309.*
17. **Klein R., Berg P.A.:** Anti-mitochondrial antibodies (anti-M7) in heart disease recognize epitopes on bacterial and mammalian sarcosine dehydrogenase. *Clin. Exp. Immunol. (1990), 82(2): 289-293.*
18. **Wallukat G., Morwinski M., Kowal K., Forster A., Boewer V., Wollenberger A.:** Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitisation. *Eur. Heart J. (1991), 12 Suppl. D: 178-181.*
19. **Neumann D.A., Burek C.L., Baughman K.L., Rose N.R., Herskovitz A.:** Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. *J. Am. Coll. Cardiol. (1990), 16(6): 839-846.*

20. **Schultheiß H.-P.:** The significance of autoantibodies against the ADP/ATP-carrier for the pathogenesis of myocarditis and dilated cardiomyopathy – clinical and experimental data. *Springer Semin. Immunopathol.* (1989), 11(1): 15-30.
21. **Schulze K., Becker B.F., Schauer R., Schultheiß H.-P.:** Antibodies to the ADP/ATP carrier -an autoantigen in myocarditis and dilated cardiomyopathy- impair cardiac function. *Circulation* (1990), 81(3): 959-969.
22. **Schulze K., Becker B.F., Schultheiß H.-P.:** Antibodies to the ADP/ATP carrier -- an autoantigen in myocarditis and dilated cardiomyopathy – penetrate into myocardial cells and disturb energy metabolism in vivo. *Circulation* (1989), 64(2): 179-192.
23. **Herzum M., Weller R., Jomaa H., Wietzychowski F., Pankuweit S., Mahr P., Maisch B.:** Left ventricular Hemodynamic Parameters in the Course of Acute Experimental Coxsackievirus B3 Myocarditis. *J. Mol. Cell. Cardiol.* (1995), 27: 1573-1580.
24. **Smith S.C., Allen P.M.:** Myosin-induced acute myocarditis is a T-cell-mediated disease. *J. Immunol.* (1991), 147(7): 2141-2147.
25. **Bosma M.J., Carrol A.M.:** The scid mouse mutant: Definition, characterization and potential uses. *Annu. Rev. Immunol.* (1991), 9: 323-350.
26. **Custer R.P., Bosma G.C., Bosma M.J.:** Severe combined immunodeficiency (SCID) in the mouse-pathology, reconstitution, neoplasms. *Am. J. Pathol.* (1985), 120(3): 464-477.
27. **Hendrickson E.A., Xiao-Qiang Q., Bump E.A., Schatz D.G., Oettinger M., Weaver D.T.:** A link between double-strand break-related repair and V(D)J recombination: The scid mutation. *Proc. Natl. Acad. Sci. USA* (1991), 88: 4061-4065.
28. **Phillips R.A., Jewett M.A.S., Gallie B.L.:** Growth of human tumors in immune-deficient scid mice and nude mice. *Curr. Top. Microbiol. Immunol.* (1989), 152: 259-263.
29. **Moisier D.E., Gulizia R.J., Baird S.M., Wilson D.B.:** Transfer of a functional human immune system to mice with severe combined immunodeficiency. *Nature* (1988), 335: 256-259.

30. Report of the 1995 WHO/ISFC task force on the definition and classification of cardiomyopathies. *Circulation* (1996); 93: 841-842.
31. **Aretz H.T.:** Myocarditis: The DALLAS´criteria. *Hum. Pathol.* (1987), 18(6): 619-624.
32. **Kumar V., Hackett J., Tutt M.M., Garni-Wagner B.A., Kuziel W.A., Tucker P.W., Bennett M.:** Natural killer cells and their precursors in mice with severe combined immunodeficiency. *Curr. Top. Microbiol. Immunol.* (1989), 152: 47-52.
33. **Bosma G.C., Custer R.P., Bosma M.J.:** A severe combined immunodeficiency mutation in the mouse. *Nature* (1983), 301: 527-530.
34. **Blay R., Simpson K., Leslie K., Huber S.A.:** Coxsackievirus-induced disease: CD4⁺-cells initiate both myocarditis and pancreatitis in DBA/2 mice. *Am. J. Pathol.* (1989), 135(5): 899-907.
35. **Lodge P.A., Herzum M., Olszewski J., Huber S.A.:** Coxsackievirus B3 myocarditis: Acute and chronic forms of the disease caused by different immunopathogenic mechanisms. *Am. J. Pathol.* (1987), 128(3): 455-463.
36. **Alvarez F.L., Neu N., Rose N.R., Craig S.W., Beisel K.W.:** Heart-specific autoantibodies induced by Coxsackievirus B3: Identification of heart autoantigens. *Clin. Immunol. Immunopathol.* (1987), 43: 129-139.
37. **Rose N.R., Neumann D.A., Herskovitz A.:** Autoimmune myocarditis – concepts and questions. *Immunol. Today* (1991), 12(8): 153-133.
38. **Schwimmbeck P.L., Schultheiß H.-P., Strauer B.E.:** Identification of a main autoimmunogenic epitope of the adenine nucleotide translocator which cross-reacts with coxsackie B3 virus. Use in diagnosis of myocarditis and dilated cardiomyopathy. *Circulation* (1989), 90 Suppl. II: 665ff.
39. **Oldstone M.B.A., Dryberg Th., Fujinami R.:** Mimicry by virus of host molecules -Implications for autoimmune disease. *Prog. Immunol.* (1986), 787-795.
40. **Klingenberg M., Heldt H.W.:** The ADP/ATP translocation in mitochondria and its role in intracellular compartmentation. In: *Metabolic compartmentation* (Ed.: H. Sies). Academic Press, London (1982), 101-122.

41. **Barry T.S., Jones D.M., Richter C.B., Haynes B.F.:** Successful engraftment of human postnatal thymus in severe combined immunodeficiency (SCID) mice: Differential engraftment of thymic components with irradiation versus anti-asialo GM-1 immunosuppressive regimens. *J. Exp. Med.* (1991), 173: 167-180.
42. **Norton F.L., Shuey S.R., Köhler H.:** Response of huSCID mice reconstituted with lymphocytes from anti-idiotype-treated melanoma patients. *Clin. Immunol. Immunopath.* (1991), 61: 332-342.
43. **Moisier D.E., Gulizia R.J., Baird S.M., Wilson D.B.:** Transfer of a functional human immune system to mice with severe combined immunodeficiency. *Nature* (1988), 335: 256-259.
44. **Phillips R.A., Jewett M.A.S., Gallie B.L.:** Growth of human tumors in immunodeficient scid mice and nude mice. *Curr. Top. Microbiol. Immunol.* (1989), 152: 259-263.
45. **Benfield M.R., Witson J.C., Alter B.J., Bach F.H.:** Human anti-murine mixed leucocyte culture: Effects of cytokines. *Transpl. Proc.* (1991), 23(1): 219.
46. **Shulman H.M., Sullivan K.M., Weiden P.L., McDonald G.B., Striker G.E., Sale G.E., Hackman R., Tsoi M., Storb R., Thomas E.D.:** Chronic graft-versus-host syndrome in man: a long-term clinicopathologic study of 20 Seattle patients. *Am. J. Med.* (1980), 69: 204-217.
47. **Bankert R.B., Umemoto T., Sugiyama Y., Chen F.A., Repasky E., Yokota S.:** Human lung tumors, Patient's peripheral blood lymphocytes and tumor infiltrating lymphocytes propagated in SCID mice. *Curr. Top. Microbiol. Immunol.* (1989), 152: 201-210.
48. **Schultheiß H.-P.:** The significance of autoantibodies against the ADP/ATP-carrier for the pathogenesis of myocarditis and dilated cardiomyopathy – clinical and experimental data. *Springer Semin. Immunopathol.* (1989), 11(1): 15-30.
49. **Schultheiß H.-P., Bolte H.D.:** Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. *J. Mol. Cell. Cardiol.* (1985), 17: 603-617.
50. **Miller M.D., Krangel M.S.:** Biology and Biochemistry of the Chemokines: A Family of Chemotactic and Inflammatory Cytokines. *Critic. Rev. Immun.* (1992), 12(1.2): 17-46.

51. **Taub D.D., Oppenheim J.J.:** Review of the Chemokine Meeting The Third International Symposium of Chemotactive Cytokines. *Cytokine* (1993), 5(3): 175-179.
52. **Hirano T.:** Interleukin-6 and Its Relation to Inflammation and Disease. *Clin. Immunol. Immunopathol.* (1992), 62(1): 60-65.
53. **Kishimoto T.:** Interleukin-6 and Its Receptor; From Cloning to Clinic. *Int. Arch. Allergy Immunol.* (1992), 99: 172-177.
54. **Abdallah A.N., Billes M.A., Attia Y., Doutremepuich C., Cassaigne A., Iron A.:** Evaluation of plasma levels of tumor necrosis factor alpha and interleukin-6 as rejection markers in a cohort of 142 heart-grafted patients followed by endomyocardial biopsy. *Eur. Heart J.* (1997), 18: 1024-1029.
55. **Hirano T., Akira s., Taga T., Kishimoto T.:** Biological and clinical aspects of Interleukin-6. *Immunol. Today* (1990), 11(12): 443-448.
56. **Uyttenhove C., Coulie P.G., van Snick J.:** T-Cell Growth and Differentiation induced by Interleukin-HP1/IL-6, The Murine Hybridoma/Plasmocytoma Growth Factor. *J. Exp. Med.* (1988), 167: 1417-1427.
57. **Kishimoto T., Akira s., Taga T.:** Interleukin-6 and Its Receptor: A Paradigm for Cytokines. *Science* (1992), 258: 593-597.
58. **Hirano T.:** The Biology of Interleukin-6. *Mol. Biol. Immunol.* (1992), 51: 153-180.
59. **Gaulton G.N., Williamson P.:** Interleukin-2 and the Interleukin-2-Receptor Complex. *Chem. Immunol. Basel, Karger* (1994), 59: 91-114.
60. **Matsushima K., Baldwin E.T., Mukaida N.:** Interleukin-8 and MCAF: Novel Leukocyte Recruitment and Activating Cytokines. *Chem. Immunol. Basel, Karger* (1992), 51: 236-265.
61. **Rubin L.A., Nelson D.L.:** The soluble interleukin-2-receptor: Biology, function and clinical application. *Ann. Int. Med.* (1990), 113: 619-627.
62. **Shibata S., Asano T., Noguchi A., Naito M., Ogura A., Doi K.:** Peritoneal macrophages play an important role in eliminating human cells from severe combined immunodeficient mice transplanted with human peripheral blood lymphocytes. *Immunology* (1998), 93(4): 524-532.

63. **Torbett B.E., Picchio G., Moisiert D.E.:** Hu-PBL-SCID-mice: A model for human immune function, AIDS and lymphomagenesis. *Immunol. Rev.* (1991), 124: 139-163.
64. **Murphy W.J., Bennett M., Anver M.R., Baseler M., Longo D.L.:** Human-mouse lymphoid chimeras: host-vs.-graft and graft-vs.-host reaction. *Eur. J. Immunol.* (1992), 22: 1421-1427.
65. **Shpitz B., Chambers C.A., Singhal A.B., Hozumi N., Fernandes B.J., Roifman C.M., Weiner L.M., Roder J.C., Gallinger S.:** High level functional engraftment of severe combined immunodeficient mice with human peripheral blood lymphocytes following pretreatment with radiation and anti-asialo GM1. *J. Immunol. Methods* (1994), 169(1): 1-15.
66. **Smith E., Abedi M.R., Islam K.B., Johansson M.E., Christensson B., Hammarström L.:** Humoral immunity in SCID mice reconstituted with cells from immunoglobulin-deficient or normal humans. *Immunol. Rev.* (1991), 124: 113-137.
67. **Duchosal M.A., Eming S.A., McConahey P.J., Dixon F.J.:** The hu-PBL-SCID-mouse model. Long-term human serologic evolution associated with the xenogenic transfer of human peripheral blood leucocytes into SCID mice. *Cell. Immunol.* (1992), 139(2): 468-477.
68. **Abedi M.R., Christensson B., Islam K.B., Hammarström L., Smith C.I.E.:** Immunoglobulin production in severe combined immunodeficiency mice reconstituted with human peripheral blood mononuclear cells. *Eur. J. Immunol.* (1992), 22: 823-828.
69. **Macht L., Fukuma N., Leader K., Sarsero D., Pegg C.A.S., Phillips D.I.W., Yates P., McLachlan S.M., Elson C., Smith B.R.:** Severe combined immunodeficient (SCID) mice: a model for investigating human thyroid autoantibody synthesis. *Clin. Exp. Immunol.* (1991), 84: 34-42.
70. **Macht L.M., Corrall R.J., Banga J.P., Elson C.J.:** Control of human thyroid autoantibody production in SCID mice. *Clin. Exp. Immunol.* (1993), 91(3): 390-396.

71. **Martin A., Kimura H., Thung S., Fong P., Shultz L.D., Davies T.F.:** Characteristics of long-term human thyroid peroxidase autoantibody secretion in scid mice transplanted with lymphocytes from patients with autoimmune thyroiditis. *Int. Arch. Allergy Immunol.* (1992), 98(4): 317-323.
72. **Davies T.F., Kimura H., Fong P., Kendler D., Shultz L.D., Thung S., Martin A.:** The SCID-hu Mouse and Thyroid Autoimmunity: Characterization of Human Thyroid Autoantibody Secretion. *Clin. Immunol. Immunopathol.* (1991), 60: 319-330.
73. **Duchosal M.A., McConahey P.J., Robinson C.A., Dixon F.J.:** Transfer of Human Systemic Lupus Erythematosus in Severe Combined Immunodeficient (SCID) Mice. *J. Exp. Med.* (1990), 172: 985-988.
74. **Dickey W.D., Harley J.B., Scofield R.H.:** Human autoantibody production in the severe combined immunodeficiency (scid) mouse. *Clin. Exp. Rheumatol.* (1994), 12(2): 157-161.
75. **Ashany D., Hines J., Gharavi A., Mouradian J., Elkton K.B.:** Analysis of autoantibody production in SCID-systemic lupus erythematosus (SLE) chimeras. *Clin. Exp. Immunol.* (1992), 88(1): 84-90.
76. **Tighe H., Silverman G.J., Kozin F., Tucker R., Gulizia R., Peebles C., Lotz M., Rhodes G., Machold K., Moisiere D.E., Carson D.A.:** Autoantibody production by severe combined immunodeficient mice reconstituted with synovial cells from rheumatoid arthritis patients. *Eur. J. Immunol.* (1990), 20: 1843-1848.
77. **Schwimmbeck P.L., Badorff C., Schultheiss H.P., Strauer B.E.:** Transfer of human myocarditis into severe combined immunodeficiency mice. *Circ. Res.* (1994), 75(1): 156-164.
78. **Krams S.M., Dorshkind K., Gershwin M.E.:** Generation of Biliary Lesions After Transfer Of Human Lymphocytes Into Severe Combined Immunodeficient (SCID) Mice. *J. Exp. Med.* (1989), 170:1919-1930.

79. **Abedi M.R., Hammarstrom L., Broome U., Angelin B., Smith C.I., Christensson B.:** Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). *Clin. Exp. Immunol.* (1996), 105(2): 266-273.
80. **Coccia M.A., Weeks S.J., Knott C.L., Kuus-Reichel K.:** Human IL-6 enhances human lymphocyte engraftment and activation but not human antibody production in SCID-hu-PBL-Mice. *Immunobiology* (1998), 198(4): 396-407.
81. **Hirano T., Matsuda T., Turner M., Miyasaka N., Buchan G., Tang B., Sato K., Shimizu M., Maini R., Feldman M., Kishimoto T.:** Excessive production of interleukin6/B-cell regulatory-factor-2 in rheumatoid arthritis. *Eur. J. Immunol.* (1988), 11: 1797-1801.
82. **Houssiau F.A., Devogelaer J.-P., Van Damme J., De Deuxchaisnes C.N., Van Snick J.:** Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory diseases. *Arthritis Rheum.* (1988), 31: 784-788.
83. **Matsuno H., Sawai T., Nezuka T., Uzuki M., Tsuji H., Nishimoto N., Yoshizaki K.:** Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis implants in the SCID mouse model. *Arthritis Rheum.* (1988), 41(11): 2014-2021.
84. **Badolato R., Oppenheim J.J.:** Role of cytokines, acute-phase proteins and chemokines in the progression of rheumatoid arthritis. *Semin. Arthritis Rheum.* (1996), 26(2): 526-538.
85. **Rubin L.A., Nelson D.L.:** The soluble interleukin-2-receptor: Biology, function and clinical application. *Ann. Int. Med.* (1990), 113: 619-627.
86. **Fukuta S., Yoshinaga T., Yamakawa K., Kimura Y., Kusukawa R.:** Dilated cardiomyopathy with special reference to humoral immunity. *Jap. Circ. J.* (1992), 56: 1073-1080.
87. **Ueno Y., Ichihara T., Hasui M., Maruyama H., Miyawaki T., Taniguchi N., Komiyama A.:** T-cell-dependent production of IgG by human cord blood B-cells in reconstituted SCID-mice. *Scand. J. Immunol.* (1992), 35: 415-419.

88. **Moisier D.E., Gulizia R.J., Torbett B.E.:** Break for SCID's. *Nature* (1991), 353: 509.
89. **Vassalli P.:** The pathophysiology of tumor necrosis factors. *Annu. Rev. Immunol.* (1992), 10: 411-452.
90. **Saxon A., Macy E., Denis K., Tary-Lehmann M., Witte O., Braun J.:** Limited B-cell repertoire in severe combined immunodeficiency mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. *J. Clin. Invest.* (1991), 87: 657-665.
91. **Simpson E., Farrant J., Chandler P.:** Phenotypic and functional studies of human peripheral blood lymphocytes engrafted in SCID-mice. *Immunol. Rev.* (1991), 124: 97-111.
92. **Pfeffer K., Heeg K., Bubeck R., Conradt P., Wagner H.:** Adoptive transfer of human peripheral blood lymphocytes (PBL) in SCID-mice. *Curr. Top. Microbiol. Immunol.* (1989), 152: 211-217.
93. **Seitz M., Dewald B., Gerber N., Baggiolini M.:** Enhanced production of neutrophil-activating peptide-1/IL-8 in rheumatoid arthritis. *J. Clin. Invest.* (1991), 87: 463 ff.
94. **Koch A.E., Kunkel S.L., Burrows J.C., Evanoff H.L., Haines G.K., Pope R.M., Strieter R.M.:** Synovial tissue macrophages as a source of the chemotactic cytokine IL-8. *J. Immunol.* (1991), 147: 2187 ff.
95. **Oppenheim J.J., Zachariae C.O.C., Mukaida N., Matsushima K.:** Properties of the novel proinflammatory supergene „intercrine“ cytokine family. *Annu. Rev. Immunol.* (1991), 9: 617-648.
96. **Purtillo D.T., Falk K., Pirruccello S.J., Nakamine H., Kleveland K., Davis J.R., Okano M., Taguchi Y., Sanger W.G., Beisel K.W.:** SCID mouse model of Epstein-Barr Virus- induced lymphomagenesis of immunodeficient humans. *Int. J. Cancer* (1991), 47: 510-517.
97. **Sullivan K.M., Shulman H.M., Storb R., Weiden P.L., Witherspoon R.P., McDonald G.B., Schubert M.M., Atkinson K., Donnall-Thomas E.:** Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. *Blood* (1981), 57(2): 267-276.

98. **Alter B.J., Bach F.H.:** Cellular basis of the proliferative response of human T-cells to mouse xenoantigens. *J. Exp. Med.* (1990), 171: 333-338.
99. **Carlsson R., Martensson C., Kalliomäki S., Ohlin M., Borrebaeck C.A.:** Human peripheral blood lymphocytes transplanted into SCID mice constitute an in vivo culture system exhibiting several parameters found in a normal humoral immune response and are a source of immunocytes for the production of human monoclonal antibodies. *J. Immunol.* (1992), 148(4): 1065-1071.
100. **Rowe M., Young L.S., Crocker J., Stokes H., Henderson S., Rickinson A.B.:** Epstein-Barr-Virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man. *J. Exp. Med.* (1991), 173: 147-158.
101. **Bosma G.C., Fried M., Custer R.P., Carroll A., Gibson D.M., Bosma M.J.:** Evidence of functional lymphocytes in some (leaky) SCID mice. *J. Exp. Med.* (1988), 167: 1016-1033.
102. **Zimin Y.I., Sumarokov A.V., Tereshchenko S.E.:** Immune cytotoxic mechanism of myocardial lesion in non-specific Myocarditis and idiopathic congestive cardiomyopathy. *COR VASA* (1988), 30 (2): 127-134.
103. **Behm E.:** Immunodiffusion. In: *Immunologische Arbeitsmethoden* (Ed.: H. Friemel). Gustav Fischer Verlag, Jena (1991), 81-93.
104. **Riccio P., Aquila H., Klingenberg M.:** Solubilization of the carboxyatractylate binding protein from mitochondria. *FEBS Letters* (1975), 56: 129-132.
105. **Riccio P., Aquila H., Klingenberg M.:** Purification of the carboxyatractylate binding protein from mitochondria. *FEBS Letters* (1975), 56: 133-138.
106. **Eiermann W., Aquila H., Klingenberg M.:** Immunological characterization of the ADP/ATP translocator protein isolated from mitochondria of liver, heart and other organs. *FEBS Letters* (1977), 74: 209-214.
107. **Cozens A.L., Runswick M.J., Walker J.E.:** DNA sequences of two expressed nuclear genes for human mitochondrial ADP/ATP translocase. *J. Mol. Biol.* (1989), 206: 261-280.
108. **Lowry O.L., Rosebrough N.J., Farr A.L., Randall R.J.:** Protein measurement with the FOLIN phenol reagent. *J. Biol. Chem.* (1951), 193: 265-275.

109. **Garewal H.S.:** A procedure for the estimation of microgram quantities of Triton X-100. *Analyt. Biochem.* (1973), 54: 329-334.
110. **Holloway P.W.:** A simple procedure for removal of Triton X-100 from protein samples. *Analyt. Biochem.* (1973), 53: 304-308.
111. **Schultheiß H.-P., Bolte H.D.:** Immunological analysis of autoantibodies against the adenine nucleotide translocator in dilated cardiomyopathy. *J. Mol. Cell. Cardiol.* (1985), 17: 603-617.
112. **Nakamine H., Okano M., Taguchi Y., Pirruccello S.J., Davies J.R., Beisel K.W., Kleveland K., Sanger W.G., Fordyce R.R., Purtilo D.T.:** Hematopathologic features of Epstein-Barr-Virus-induced human B-lymphoproliferation in mice with severe combined immunodeficiency. A model of lymphoproliferative diseases in immunocompromised patients. *Lab. Inv.* (1991), 54(4): 389-399.
113. **Ramm B., Hofmann G.:** Biomathematik. *Enke Verlag, Stuttgart* (1987).
114. **Werner J.:** Biomathematik und Medizinische Statistik. *Verlag Urban & Schwarzenberg, München* (1992).
115. **James K.B., Lee K., Thomas J.D., Hobbs R.E., Rincon G., Bott-Silverman C., Ratliff N., Marchant K., Klein A.L.:** Left ventricular diastolic dysfunction in lymphocytic myocarditis as assessed by doppler echocardiography. *Am. J. Cardiol* (1984), 73: 282-285.
116. **Herzum M., Mahr P., Wietrzychowski F., Jomaa H., Weller R., Spengler D., Ruppert V., Maisch B.:** Left ventricular haemodynamics in murine viral myocarditis. *European Heart Journal* (1995), 16 (Suppl. O), 28-30.
117. **Friman G., Wesslen L., Fohlman J., Karjalainen J., Rolf C.:** The epidemiology of infectious myocarditis, lymphocytic myocarditis and dilated cardiomyopathy. *European Heart Journal* (1995), 16 (Suppl. O), 36-41.
118. **Schulze-Koops H., Lipsky P.E., Kavanaugh A.F., Davis L.S.:** Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis after treatment with a monoclonal antibody to CD54 (ICAM-1). *Clin. Exp. Immunol.* (1996), 106 (2): 190-6.
119. **Rose N.R., Hill S.L.:** The pathogenesis of postinfectious myocarditis. *Clin. Immunol. Immunopathol.* (1996), 80 (3Pt 2): S92-9

120. **Gauntt C.J., Tracy S.M., Chapman N., Wood H.J., Kolbeck P.C., Karaganis A.G., Winfrey C.L., Cunningham M.W.:** Coxsackievirus-induced chronic myocarditis in murine models. *Eur. Heart J. (1995), 16 (Suppl. O): 56-8.*
121. **Adler D., Monrad E.S., Hess O.M., Krayenbuehl H.P., Sonnenblick E.H.:** Time to dP/dt (max), a useful index for evaluation of contractility in the catheterization laboratory. *Clin. Cardiol. (1996), 19 (5): 397-403.*
122. **Watson P.F., Pickerill A.P., Davies R., Weetman A.P.:** Semi-Quantitative analysis of interleukin-1 alpha, IL-6 and IL-8 mRNA expression by human thyreocytes. *J. Mol. Endocrinol. (1995), 15 (1): 11-21.*
123. **Badolato R., Oppenheim J.J.:** Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. *Semin. Arthritis Rheum. (1996), 26 (2). 526-38.*
124. **Doerner A., Schulze K., Rauch U., Schultheiss H.P.:** Adenine nucleotide translocator in dilated cardiomyopathy: pathophysiological alterations in expression and function. *Mol. Cell. Biochem. (1997), 174 (1-2): 261-9.*
125. **Pauschinger M., Kühl U., Doerner A., Schieferecke K., Petschauer S., Rauch U., Schwimmbeck P.L., Kandolf R., Schultheiss H.P.:** Nachweis enteroviraler RNA in endomyokardialen Biopsien bei inflammatorischer Kardiomyopathie und idiopathischer dilatativer Kardiomyopathie. *Z. Kardiol. (1998), 87 (6): 443-52.*
126. **Kuhl U., Noutsias M., Seeberg B., Schannwell M., Welp L.B., Schultheiß H.P.:** Chronic inflammation in the myocardium of patients with clinically suspected dilated cardiomyopathy. *J. Card. Fail. 1994 Oct; 1(1):13-25.*
127. **Mann D.L.:** Interleukin-6 and viral myocarditis: the Yin-Yang of cardiac innate immune responses. *J. Moll. Cell. Cardiol. 2001 Sep; 33 (9): 1551-3.*
128. **Sarda L., Colin P., Boccara F., Daou D., Lebtahi R., Faraggi M., Nguyen C., Cohen A., Slama M.S., Steg P.G., Le Guludec D.:** Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. *J. Am. Coll. Cardiol. 2001 Mar 1; 37 (3): 786-92.*

129. **Kivelitz D.E., Enzweiler C.N., Wiese T.H., Lembcke A., Borges A., Zytowski M., Taupitz M., Hamm B.:** Determination of left ventricular function parameters and myocardial mass: comparison of MRI and EBT: *Rofo. Fortschr. Geb. Rontgenstr. Neuen Bildgeb. Verfahr.* 2000 Mar; 172 (3): 244-50.
130. **Malkiel S., Factor S., Diamond B.:** Autoimmune myocarditis does not require B cells for antigen presentation. *J. Immunol.* 1999 Nov 15; 163 (10): 5265-8.
131. **Lauer B., Schannwell M., Kuhl U., Strauer B.E., Schultheiß H.P.:** Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. *J. Am. Coll. Cardiol.* 2000 Jan; 35 (1): 11-8.
132. **Perez Leiros C., Goren N., Sterin-Borda L., Borda E.S.:** Myocardial dysfunction in an experimental model of autoimmune myocarditis: role of IFN-gamma. *Neuroimmunomodulation.* 1997 Mar-Apr; 4 (2): 91-7.
133. **Carthy C.M., Yang D., Anderson D.R., Wilson J.E., McManus B.M.:** Myocarditis as systemic disease: new perspectives on pathogenesis. *Clin. Exp. Pharmacol. Physiol.* 1997 Dec; 24 (12): 997-1003.
134. **Caforio A.L., Baboonian C., McKenna W.J.:** Postviral autoimmune heart disease-fact or fiction? *Eur. Heart J.* 1997 Jul; 18 (7): 1051-5.
135. **Huber S.A.:** Autoimmunity in myocarditis: relevance of animal models. *Clin. Immunol. Immunopathol.* 1997 May; 83 (2): 93-102.
136. **Less H., Shilkrut M., Rubinstein I., Berke G., Binah O.:** Cardiac dysfunction in murine autoimmune myocarditis. *J. Autoimmun.* 1999 May; 12 (3): 209-20.
137. **Friedman B.J., Grinberg O.Y., Ratcliffe N.R., Swartz H.M., Hickey W.F.:** Acute hemodynamic and coronary circulatory effects of experimental autoimmune myocarditis. *Heart Vessels.* 1998; 13 (2): 58-62.
138. **Luppi P., Rudert W.A., Zanone M.M., Stassi G., Trucco G., Finegold D., Boyle G.J., Del Nido P., McGowan F.X., Trucco M.:** Idiopathic dilated cardiomyopathy. A superantigen-driven autoimmune disease. *Circulation.* 1998 Aug 25; 98 (8): 777-85.
139. **Sigusch H.H., Reinhardt D., Figulla H.R.:** Clinical picture and differential diagnosis of cardiomyopathy and myocarditis. *Med. Klin.* 1998 Apr 15; 93 (4): 236-9.

140. **Pankuweit S., Hufnagel G., Eckhardt H., Herrmann H., Uttecht S., Maisch B.:** Cardiotropic DNA viruses and bacteria in the pathogenesis of dilated cardiomyopathy with or without inflammation. *Med. Klin.* 1998 Apr 15; 93 (4): 223-8.
141. **Huber S.A., Budd R.C., Rossner K., Newell M.K.:** Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy. *Ann. N.Y. Acad. Sci.* 1999; 877: 181-90.
142. **Lawson C.M.:** Evidence for mimicry by viral antigens in animal models of autoimmune disease including myocarditis. *Cell. Mol. Life Sci.* 2000 Apr; 57 (4): 552-60.
143. **Ratcliffe N.R., Hutchins J., Barry B., Hickey W.F.:** Chronic myocarditis induced by T cells reactive to a single cardiac myosin peptide: persistent inflammation, cardiac dilatation, myocardial scarring and continuous myocyte apoptosis. *J. Autoimmun.* 2000 Nov; 15 (3): 359-67.
144. **Izumi T., Takehana H., Matsuda C., Yokoyama H., Kohno K., Suzuki K., Inomata T.:** Experimental autoimmune myocarditis and its pathomechanism. *Herz.* 2000 May; 25 (3): 274-8.
145. **Penninger J.M., Bachmaier K.:** Review of microbial infections and the immune response to cardiac antigens. *J. Infect Dis.* 2000 Jun; 181 Suppl 3: S498-504.
146. **Kitabayashi H., Isobe M., Watanabe N., Suzuki J., Yazaki Y., Sekiguchi M.:** FTY720 prevents development of experimental autoimmune myocarditis through reduction of circulating lymphocytes. *J. Cardiovasc. Pharmacol.* 2000 Mar; 35 (3): 410-6.
147. **Caforio A.L., Mahon N.J., Mckenna W.J.:** Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy. *Autoimmunity.* 2001; 34 (3): 199-204.
148. **Kohno K., Takagaki Y., Aoyama N., Yokoyama H., Takehana H., Izumi T.:** A peptide fragment of beta cardiac myosin heavy chain (beta-CMHC) can provoke autoimmune myocarditis as well as the corresponding alpha cardiac myosin heavy chain (alpha-CMHC) fragment. *Autoimmunity.* 2001; 34 (3): 177-85.

149. **Hill S.L., Rose N.R.:** The transition from viral to autoimmune myocarditis. *Autoimmunity*. 2001; 34 (3): 169-76.
150. **Furukawa Y., Kobuke K., Matsumori A.:** Role of cytokines in autoimmune myocarditis and cardiomyopathy. *Autoimmunity*. 2001; 34 (3): 165-8.
151. **Benoist C., Mathis D.:** Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? *Nat. Immunol*. 2001 Sep; 2 (9): 797-801.
152. **Fairweather D., Kaya Z., Shellam G.R., Lawson C.M., Rose N.R.:** From infection to autoimmunity. *J. Autoimmun*. 2001 May; 16 (3): 175-86.
153. **Godsel L.M., Wang K., Schodin B.A., Leon J.S., Miller S.D., Engman D.M.:** Prevention of autoimmune myocarditis through the induction of antigen-specific peripheral immune tolerance. *Circulation*. 2001 Mar 27; 103 (12): 1709-14.

Danksagung

Mein Dank gilt allen, die mir bei der Durchführung dieser Arbeit behilflich waren, insbesondere:

Herrn Prof. Dr. H.-P. Schultheiß für die Überlassung des interessanten Themas und für den großen Freiraum bei dessen Bearbeitung;

Herrn Prof. Dr. P.L. Schwimmbeck für seine Betreuung, die vielen Anregungen und Ratschläge, die fruchtbaren Diskussionen, die notwendigen Korrekturen und sein Durchhaltevermögen;

Herrn Dr. K. Schulze für die Beratung bei technischen Fragen und die tatkräftige Unterstützung bei der Bearbeitung der Hämodynamik;

Herrn Dr. C. Badorff für die Einarbeitung in die Problematik;

Herrn R. Drever für die umfangreiche Unterstützung bei der Datenverarbeitung und der Veröffentlichung;

Frau S. Knüppel für Ihre Unterstützung bei der Durchführung und Auswertung der Durchflußzytometrie;

Frau A. Badorff für Ihre Unterstützung bei der Durchführung und Überwachung der Lymphozytenisolierung;

Herrn Prof. Dr. H. Zeichhardt für die Erstellung des Zweitgutachtens;

Dem gesamten Team des kardiologischen Forschungslaboratoriums am Klinikum Benjamin Franklin für die vielfältige Unterstützung bei den vielen Kleinigkeiten und für die gute Arbeitsatmosphäre;

Meinen Eltern, die mir Ausbildung und Studium ermöglicht haben;

Mein besonderer Dank aber gilt **meiner Frau Brinja-Lara**, die mich mit unendlicher Geduld unter oft großen Entbehrungen immer unterstützt hat und stets an mich geglaubt hat.